Literature DB >> 21717074

A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors.

Sudesh Pawaria1, Michelle Nicole Messmer, Yu Jerry Zhou, Robert Julian Binder.   

Abstract

For over 100 years, it has been established that tumor-specific immune responses can frequently be detected in the tumor-bearing host. Whether or not these immune responses are capable of controlling the growth of the tumor is influenced by many factors. However, the mechanism by which the immune responses are initiated in the first place has remained a dilemma. In this chapter, we present evidence that heat shock protein-peptide complexes released by tumor cells are the entity responsible for initiating the immune responses. Interaction of the extracellular HSP with its receptor CD91 is necessary for priming the immune response. We propose that the disruption of the HSP-CD91 interaction may be an active mechanism by which tumors prevent the generation of immune responses against it.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717074      PMCID: PMC3362320          DOI: 10.1007/s12026-011-8221-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  51 in total

1.  Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells.

Authors:  R J Binder; M L Harris; A Ménoret; P K Srivastava
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

2.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

3.  Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.

Authors:  Devi SenGupta; Philip J Norris; Todd J Suscovich; Mina Hassan-Zahraee; Howell F Moffett; Alicja Trocha; Rika Draenert; Philip J R Goulder; Robert J Binder; Daniel L Levey; Bruce D Walker; Pramod K Srivastava; Christian Brander
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

4.  Essential role of CD91 in re-presentation of gp96-chaperoned peptides.

Authors:  Robert J Binder; Pramod K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

5.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Authors:  Filiberto Belli; Alessandro Testori; Licia Rivoltini; Michele Maio; Giovanna Andreola; Mario Roberto Sertoli; Gianfrancesco Gallino; Adriano Piris; Alessandro Cattelan; Ivano Lazzari; Matteo Carrabba; Giorgio Scita; Cristina Santantonio; Lorenzo Pilla; Gabrina Tragni; Claudia Lombardo; Flavio Arienti; Alfonso Marchianò; Paola Queirolo; Francesco Bertolini; Agata Cova; Elda Lamaj; Lucio Ascani; Roberto Camerini; Marco Corsi; Natale Cascinelli; Jonathan J Lewis; Pramod Srivastava; Giorgio Parmiani
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

6.  Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex.

Authors:  R William Vandivier; Carol Anne Ogden; Valerie A Fadok; Peter R Hoffmann; Kevin K Brown; Marina Botto; Mark J Walport; James H Fisher; Peter M Henson; Kelly E Greene
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

7.  Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.

Authors:  Aaron A R Tobian; David H Canaday; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.

Authors:  Bo Liu; Dongxia Ye; Xinxin Song; Xinhua Zhao; Linan Yi; Jietao Song; Zhiyuan Zhang; Qingzheng Zhao
Journal:  Vaccine       Date:  2008-01-22       Impact factor: 3.641

9.  Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Authors:  Vincenzo Mazzaferro; Jorgelina Coppa; Matteo G Carrabba; Licia Rivoltini; Marcello Schiavo; Enrico Regalia; Luigi Mariani; Tiziana Camerini; Alfonso Marchianò; Salvatore Andreola; Roberto Camerini; Marco Corsi; Jonathan J Lewis; Pramod K Srivastava; Giorgio Parmiani
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

10.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962

View more
  3 in total

1.  Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo.

Authors:  Michelle Nicole Messmer; Joshua Pasmowitz; Laura Elizabeth Kropp; Simon C Watkins; Robert Julian Binder
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

2.  Heat shock proteins and regulatory T cells.

Authors:  E W Brenu; D R Staines; L Tajouri; T Huth; K J Ashton; S M Marshall-Gradisnik
Journal:  Autoimmune Dis       Date:  2013-03-14

3.  Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.

Authors:  Huaguo Zheng; Lanlan Liu; Han Zhang; Fangming Kan; Shuo Wang; Yang Li; Huaqin Tian; Songdong Meng
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.